, Narjes Hazar
, Behnam Bagheri-Fahraji
, Reyhaneh Azizi
, Akram Ghadiri-Anari *
, Azadeh Nadjarzadeh
, Seyed Yaser Ghelmani
, Masoud Mirzaei
, Sayyed Saeid Khayyatzadeh
| ARTICLE INFO | ABSTRACT | |
| ORIGINAL ARTICLE | Background: Beneficial effects of vitamins and dietary supplements in the prevention and treatment of metabolic syndrome (MS) are controversial. This study aims to evaluate the association between dietary supplements intake and MS. Methods: This analytical cross-sectional analysis was conducted on 9539 people aged 35-70 years who participated in the recruitment phase of Shahedieh Cohort Study in Yazd-Iran (May 2015 to September 2017). The consumption of supplements, such as multivitamin-mineral, multivitamin, calcium-D, calcium, vitamin D, folic acid, omega 3, iron, and zinc were asked in the study. the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria used for defining MS. Results: 4785 (50.2%) men and 4754 (49.8%) women with mean age of 47.64 ± 9.60 years participated in this study. The prevalence of MS was 2901 (30.41%). The participants with MS were significantly different in consuming supplements, such as Calcium-D (P < 0.001), Calcium (P < 0.001), Calcium-D or Calcium products (P = 0.001), vitamin D; injection (P = 0.017) and vitamin D orally or injection (P = 0.005), Omega 3, fish oil (P = 0.001), and at least one supplement intake (P = 0.001). However, the relationship between MS and supplement consumption was not significant after adjusting for covariates in the multivariate regression model. Conclusion: Multiple factors may be responsible for the high prevalence of MS. It seems that a known supplement may not be the pathologic factor in the MS. Keywords: Metabolic syndrome; Oxidative stress; Vitamins |
|
| Article history: Received: 2 Aug 2021 Revised: 18 Sep 2021 Accepted: 15 Oct 2021 |
||
| *Corresponding author: ghadiriam@yahoo.com Diabetes Research Center, Talar-e-Honar Alley, Shahid Sadoughi Blvd., Yazd, Iran. Postal code: 8917693571 Tel: +98 9133534921 |
| Table 1. Demographics and frequency of supplement consumption from recruitment phase of Shahedieh Cohort study. | |
| Variables | n (%) or mean ± SD |
| Age (year) | 47.64 ± 9.60 |
| Body mass index (kg/m2) | 28.42± 4.80 |
| Sex | |
| Male | 4785 (50.2) |
| Female | 4754 (49.8) |
| Physical activity | |
| Low | 4917 (51.6) |
| Moderate | 3568 (37.4) |
| High | 1054 (11.0) |
| Smoking | 2115 (22.5) |
| Multivitamin-mineral | 315 (3.3) |
| Multivitamin | 257 (2.7) |
| Multivitamin-mineral or multivitamin | 572 (5.9) |
| Calcium-D | 1441 (15.1) |
| Calcium | 599 (6.3) |
| Calcium-D or Calcium | 2040 (21.3) |
| Vitamin D (Oral) | 1121 (11.8) |
| Vitamin D (injection) | 485 (5.1) |
| Vitamin D (oral or injection) | 1606 (16.8) |
| Folic acid | 1187 (12.4) |
| Omega 3, fish oil | 778 (8.1) |
| Iron | 1597 (16.7) |
| Zinc | 105 (1.1) |
| At least one supplement consumption | 4152 (43.5) |
| Table 2. Comparison of supplements consumption in the subjects with and without metabolic syndrome in the study population from recruitment phase of Shahedieh Cohort study. | |||||||
| Supplements consumption | Metabolic syndrome | P-valuea | |||||
| No (6638) | Yes (2901) | ||||||
| Multivitamin-mineral | 230 (3.5) | 85 (2.9) | 0.179 | ||||
| Multivitamin | 186 (2.8) | 71 (2.4) | 0.325 | ||||
| Multivitamin-mineral or Multivitamin | 416 (6.2) | 156 (5.3) | 0.090 | ||||
| Calcium-D | 934 (14.1) | 507 (17.5) | <0.001 | ||||
| Calcium | 365 (5.5) | 234 (8.1) | <0.001 | ||||
| Calcium (Total) | 1299 (19. 5) | 741 (25.5) | <0.001 | ||||
| Vitamin D (Oral) | 755 (11.4) | 366 (12.6) | 0.083 | ||||
| Vitamin D (Injection) | 314 (4.7) | 171 (5.9) | 0.017 | ||||
| Vitamin D (oral or injection) | 1069 (16.1) | 537 (18.5) | 0.005 | ||||
| Folic acid | 825 (12.4) | 362 (12.5) | 0.946 | ||||
| Omega 3 (fish oil) | 481 (7.2) | 297 (10.2) | <0.001 | ||||
| Iron | 1115 (16.8) | 482 (16.6) | 0.826 | ||||
| Zinc | 82 (1.2) | 23 (0.8) | 0.057 | ||||
| At least one supplement consumption | 2762 (41.6) | 1390 (47.9) | <0.001 | ||||
| a:chi-square test | |||||||
| Table 3. The relationship between supplement consumption and metabolic syndrome in the study population from recruitment phase of Shahedieh Cohort study. | |||||||
| Model 1 | Model 2 | Model 3 | Model 4 | ||||
| Multivitamin-mineral P-valueb |
0.83 (0.64-1.09)a 0.18 |
0.85 (0.64-1.11) 0.29 |
0.85 (0.63-1.13) 0.27 |
0.863 (0.64-1.15) 0.32 |
|||
| Multivitamin P-value |
0.88 (0.72-1.07) 0.22 |
0.93 (0.75-1.15) 0.51 |
0.92 (0.74-1.15) 0.50 |
0.96 (0.77-1.19) 0.71 |
|||
| Multivitamin, total P-value |
0.90 (0.79-1.02) 0.12 |
0.87 (0.76-1.00) 0.06 |
0.87 (0.76-1.00) 0.05 |
0.87 (0.76-1.00) 0.05 |
|||
| Calcium-D P-value |
1.12 (0.94-1.35) 0.18 |
1.09 (0.89-1.32) 0.37 |
1.09 (0.89-1.32) 0.38 |
1.08 (0.89-1.31) 0.41 |
|||
| Calcium, total P-value |
0.96 (0.86-1.08) 0.55 |
0.93 (0.82-1.05) 0.24 |
0.92 (0.82-1.04) 0.22 |
0.92 (0.82-1.04) 0.22 |
|||
| Vitamin D, tablet P-value |
0.92 (0.80-1.06) 0.28 |
0.87 (0.74-1.01) 0.07 |
0.87 (0.74-1.01) 0.07 |
0.87 (0.75-1.02) 0.09 |
|||
| Vitamin D, injection P-value |
0.90 (0.74-1.11) 0.34 |
0.82 (0.66-1.03) 0.09 |
0.82 (0.65-1.02) 0.07 |
0.82 (0.65-1.02) 0.08 |
|||
| Vitamin D, total P-value |
0.93 (0.82-1.06) 0.31 |
0.87 (0.76-1.00) 0.06 |
0.87 (0.76-1.00) 0.05 |
0.87 (0.76-1.01) 0.07 |
|||
| Omega 3, fish oil P-value |
1.08 (0.92-1.27) 0.30 |
0.95 (0.79-1.13) 0.56 |
0.94 (0.79-1.12) 0.51 |
0.93 (0.78-1.11) 0.43 |
|||
| Zinc P-value |
0.65 (0.40-1.05) 0.08 |
0.70 (0.42-1.17) 0.18 |
0.69 (0.41-1.16) 0.17 |
0.70 (0.42-1.18) 0.19 |
|||
| At least one supplement P-value |
0.97 (0.87-1.07) 0.54 |
0.95 (0.85-1.06) 0.37 |
0.94 (0.85-1.05) 0.32 |
0.94 (0.85-1.05) 0.30 |
|||
| Model 1: Adjustment for age and sex; Model 2: Adjustment for age, sex, and BMI; Model 3: Adjustment for age, sex, BMI, and physical activity; Model 4: Adjustment for age, sex, BMI, physical activity, and smoking; a: OR (95% CI); b: Logistic regression statistical test | |||||||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |